These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38222696)

  • 41. The mucopolysaccharidoses and mucolipidoses.
    Kelly TE
    Clin Orthop Relat Res; 1976; (114):116-33. PubMed ID: 131015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutation c.1190-1delG/N in intron 8 and c.1708G>C/N in exon 12 not reported in the IDUA gene developed a clinical phenotype of Scheie syndrome.
    Delgado Luengo WN; Miranda Contreras LE; Chávez CJ; Solis-Añez E; Cammarata-Scalisi F
    Invest Clin; 2014 Dec; 55(4):365-70. PubMed ID: 25558755
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I.
    Pastores GM; Arn P; Beck M; Clarke JT; Guffon N; Kaplan P; Muenzer J; Norato DY; Shapiro E; Thomas J; Viskochil D; Wraith JE
    Mol Genet Metab; 2007 May; 91(1):37-47. PubMed ID: 17336562
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of a novel compound heterozygous IDUA mutation underlies Mucopolysaccharidoses type I in a Chinese pedigree.
    Zhou YA; Li P; Zhang Y; Xiong Q; Li C; Zhao Z; Wang Y; Xiao H
    Mol Genet Genomic Med; 2020 Jan; 8(1):e1058. PubMed ID: 31758674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry.
    Clarke LA; Giugliani R; Guffon N; Jones SA; Keenan HA; Munoz-Rojas MV; Okuyama T; Viskochil D; Whitley CB; Wijburg FA; Muenzer J
    Clin Genet; 2019 Oct; 96(4):281-289. PubMed ID: 31194252
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical manifestation of Hurler syndrome in a 7 year old child.
    Sharma S; Sabharwal JR; Datta P; Sood S
    Contemp Clin Dent; 2012 Jan; 3(1):86-9. PubMed ID: 22557905
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18-year follow-up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I.
    Pjetraj D; Santoro L; Sgattoni C; Padella L; Zampini L; Monachesi C; Gabrielli O; Catassi C
    Am J Med Genet A; 2023 Feb; 191(2):564-569. PubMed ID: 36333985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dysostosis Multiplex in Human Mucopolysaccharidosis Type 1 H and in Animal Models of the Disease.
    Hampe CS; Polgreen LE; Lund TC; McIvor RS
    Pediatr Endocrinol Rev; 2020 Aug; 17(4):317-326. PubMed ID: 32780955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry.
    D'Aco K; Underhill L; Rangachari L; Arn P; Cox GF; Giugliani R; Okuyama T; Wijburg F; Kaplan P
    Eur J Pediatr; 2012 Jun; 171(6):911-9. PubMed ID: 22234477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The alpha-L-iduronidase mutations R89Q and R89W result in an attenuated mucopolysaccharidosis type I clinical presentation.
    Hein LK; Hopwood JJ; Clements PR; Brooks DA
    Biochim Biophys Acta; 2003 Oct; 1639(2):95-103. PubMed ID: 14559116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hurler/Scheie phenotype. Report of an inbred sibship with tapeto-retinal degeneration and electron-microscopie examination of the conjuctiva.
    Jensen OA; Pedersen C; Schwartz M; Vestermark S; Warburg M
    Ophthalmologica; 1978; 176(4):194-204. PubMed ID: 96404
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Negative ERGs in mucopolysaccharidoses (MPS) Hurler-Scheie (I-H/S) and Hurler (I-H)-syndromes.
    Tzetzi D; Hamilton R; Robinson PH; Dutton GN
    Doc Ophthalmol; 2007 May; 114(3):153-8. PubMed ID: 17464575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK.
    Moore D; Connock MJ; Wraith E; Lavery C
    Orphanet J Rare Dis; 2008 Sep; 3():24. PubMed ID: 18796143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The natural history of MPS I: global perspectives from the MPS I Registry.
    Beck M; Arn P; Giugliani R; Muenzer J; Okuyama T; Taylor J; Fallet S
    Genet Med; 2014 Oct; 16(10):759-65. PubMed ID: 24675674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Mucopolysaccharidosis: A review].
    Michaud M; Belmatoug N; Catros F; Ancellin S; Touati G; Levade T; Gaches F
    Rev Med Interne; 2020 Mar; 41(3):180-188. PubMed ID: 31959364
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anaesthetic problems in Hurler-Scheie syndrome. Report of two cases.
    Sjøgren P; Pedersen T
    Acta Anaesthesiol Scand; 1986 Aug; 30(6):484-6. PubMed ID: 3096067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The development of cognitive functions in children with Hurler phenotype mucopolysaccharidosis type I on enzyme replacement therapy with laronidase].
    Biernacka M; Jakubowska-Winecka A; Tylki-Szymańska A
    Pediatr Endocrinol Diabetes Metab; 2010; 16(4):249-54. PubMed ID: 21447265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The use of alpha-L-iduronidase activity determinations in leucocytes for the detection of Hurler and Scheie syndromes.
    Liem KO; Hooghwinkel GJ
    Clin Chim Acta; 1975 Apr; 60(2):259-62. PubMed ID: 805007
    [No Abstract]   [Full Text] [Related]  

  • 59. Laronidase treatment of mucopolysaccharidosis I.
    Wraith EJ; Hopwood JJ; Fuller M; Meikle PJ; Brooks DA
    BioDrugs; 2005; 19(1):1-7. PubMed ID: 15691212
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties.
    Wraith JE
    J Inherit Metab Dis; 2001 Apr; 24(2):245-50. PubMed ID: 11405343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.